+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Esophageal Cancer Drugs Market 2019-2023 - Product Image

Global Esophageal Cancer Drugs Market 2019-2023

  • ID: 4760887
  • Report
  • March 2019
  • Region: Global
  • 118 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sanofi
  • MORE
The increasing incidence of esophageal cancer owing to factors including smoking, genetic mutations, obesity, and alcohol consumption has triggered the esophageal cancer drugs market growth in the forthcoming years.

The growing prevalence of diseases like adenocarcinoma and squamous cell carcinoma in the US is also contributing to the market’s growth. In addition, the continuous occurrence of GERD causes dysplasia, eventually, resulting in an uncontrolled growth of cells in the esophagus. This will further proliferate the esophageal cancer drugs market in the forthcoming years. The analysts have predicted that the esophageal cancer drugs market will register a CAGR of over 8% by 2023.

Market Overview

Rising awareness of esophageal cancer

One of the growth drivers of the global esophageal cancer drugs market is the rising awareness of esophageal cancer. Government of several economies and various non-government organizations are taking initiatives to increase patient awareness about esophageal cancer.

Side-effects of approved drugs

One of the challenges in the growth of the global esophageal cancer drugs market is the side-effects of approved drugs. Patients are opting for substitutes such as debulking surgery due to the side-effects of approved drugs which will hamper the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the esophageal cancer drugs market during 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE
  • Adenocarcinoma
  • Squamous cell carcinoma
PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sanofi
PART 16: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for esophageal cancer
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Bristol-Myers Squibb Company - Vendor overview
Exhibit 45: Bristol-Myers Squibb Company - Business segments
Exhibit 46: Bristol-Myers Squibb Company - Organizational developments
Exhibit 47: Bristol-Myers Squibb Company - Geographic focus
Exhibit 48: Bristol-Myers Squibb Company - Key offerings
Exhibit 49: Eli Lilly and Company - Vendor overview
Exhibit 50: Eli Lilly and Company - Business segments
Exhibit 51: Eli Lilly and Company - Organizational developments
Exhibit 52: Eli Lilly and Company - Geographic focus
Exhibit 53: Eli Lilly and Company - Segment focus
Exhibit 54: Eli Lilly and Company - Key offerings
Exhibit 55: F. Hoffmann-La Roche Ltd - Vendor overview
Exhibit 56: F. Hoffmann-La Roche Ltd - Business segments
Exhibit 57: F. Hoffmann-La Roche Ltd - Organizational developments
Exhibit 58: F. Hoffmann-La Roche Ltd - Geographic focus
Exhibit 59: F. Hoffmann-La Roche Ltd - Segment focus
Exhibit 60: F. Hoffmann-La Roche Ltd - Key offerings
Exhibit 61: Merck & Co., Inc. - Vendor overview
Exhibit 62: Merck & Co., Inc. - Business segments
Exhibit 63: Merck & Co., Inc. - Organizational developments
Exhibit 64: Merck & Co., Inc. - Geographic focus
Exhibit 65: Merck & Co., Inc. - Segment focus
Exhibit 66: Merck & Co., Inc. - Key offerings
Exhibit 67: Sanofi - Vendor overview
Exhibit 68: Sanofi - Business segments
Exhibit 69: Sanofi - Organizational developments
Exhibit 70: Sanofi - Geographic focus
Exhibit 71: Sanofi - Segment focus
Exhibit 72: Sanofi - Key offerings
Exhibit 73: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sanofi
  • MORE
Global Esophageal Cancer Drugs Market 2019-2023

The analyst recognizes the following companies as the key players in the global esophageal cancer drugs market: Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emerging novel therapies.”

According to the report, one of the major drivers for this market is the rising awareness of esophageal cancer.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of approved drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll